SPY Data Highlights High
Dr. Laura Esserman highlighted findings from the I-SPY trial regarding treatment outcomes for young women with breast cancer. The study emphasizes the need for personalized treatment strategies, particularly for those with immune-negative tumors.
Why it matters
Advancements in neoadjuvant models and personalized medicine are critical for improving survival rates and reducing treatment toxicity in oncology.
Laura Esserman, Principal Investigator at The WISDOM Study, shared a post on LinkedIn :
The content focuses on medical research and clinical trial outcomes without ideological framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in